1. Scrip
  2. >>Business
  3. >>Earnings

Moderna Sees Key Role For Respiratory Vaccines As COVID-19 Goes Endemic

 
• By Alaric DeArment

The company anticipates another year of big sales for its COVID-19 vaccine, but is also touting a pipeline of 44 programs in development, with oncology and possibly rare disease data this year.

3D_Coronavirus
Moderna announced its Q4 earnings and progress on its pipeline programs • Source: Shutterstock

With the potential for COVID-19 to transition from the current pandemic to an endemic phase on the horizon, Moderna, Inc. is playing up what comes next as it showcased its deepening pipeline of messenger RNA-based vaccines and therapeutics, including Omicron-specific candidates, during its fourth quarter and full year 2021 earnings call on 24 February.

The company still expects to rake in a hefty sum in 2022 thanks to sales of its Spikevax vaccine against SARS-CoV-2, which recently upgraded from an emergency use authorization to full US Food and Drug Administration approval. The firm anticipates the vaccine, formerly known as mRNA-1273, will generate $19bn in revenue for 2022 compared with $17

More from Earnings

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

 
• By Mandy Jackson

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

 
• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

More from Business

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

 
• By Kevin Grogan

The sector is continuing to show resilience despite financial and market challenges.